• Apabetalone development to continue to be advanced by the Company based on BETonMACE results
• Primary results to be presented during a late-breaking science session at AHA 2019 
• Apabetalone demonstrated tolerability and safety

So, the results of the trial dictate that development of this drug should be continued. Data, data, data.

Clearly, the topline does not dictate it. So, we are left with the Crestor data in isolation or the secondary and exploratory endpoints.

We know primary data will be released at the AHA. Secondary and exploratory data are expected to be released at other venues as per IR. Other conferences? Other solitary news releases?

In the conference call, Don indicated that we should wait until November 16th to see the data....which would be enlightening. One could extrapolate that positive secondary endpoints would not be released prior to that date. Otherwise, why should we have to wait until November 16 minimum?

Meanwhile, if secondary and exploratory endpoints are not going to be revealed on November 16th (and the presented data at the AHA is enlightening), I think we are looking at a near miss on the overall topline p value and a statiscally significant result for the Crestor subgroup.

RVX owns the patent to the combo drug use.

I think the market is sniffing this out.

bfw